Clinical Trial Update: CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CP-675,206 in combination with short-term androgen deprivation in stage D0 prostate cancer; trial terminated with results posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CP-675,206

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Prostate Cancer | Phase 1 | Status: TERMINATED | Results posted: 2014-05-07